Homepage
DiagnosTear develops diagnostic tools for managing eye diseases.
diagnostear.comCrawled Nov 19, 2026
DiagnosTear develops diagnostic tools for managing eye diseases.
DiagnosTear Technologies submits a pre-submission request to the U.S. Food and Drug Administration (FDA) for its TeaRx™ diagnostic test, designed to address red eye conditions. The company seeks regulatory guidance to navigate the approval process for market entry in the U.S. The submission outlines plans for TeaRx™, a potential non-invasive diagnostic tool for eye-related ailments.
DiagnosTear Technologies raises capital through a private placement of units to support its TeaRx point-of-care diagnostic development pipeline. The company advances its diagnostic tools designed for immediate clinical use. Funding will support ongoing research and product refinement in its specialized diagnostic portfolio.
DiagnosTear publishes clinical validation of its TeaRx platform, a non-invasive tear film test for dry eye disease diagnosis and treatment guidance. The study evaluates TeaRx’s multi-parametric analysis in *Current Eye Research*. Results support its use in clinical settings for objective dry eye assessment.
DiagnosTear Technologies gains exclusive worldwide rights to commercialize the CLARIFY eye imaging platform, enabling needle-free blood diagnostics. The platform leverages tear fluid analysis to provide diagnostic insights without invasive procedures. This agreement expands DiagnosTear’s capabilities in non-invasive health monitoring technologies.
DiagnosTear Technologies acquires exclusive global rights to the CLARIFY eye imaging platform, which uses eye scans to perform needle-free blood diagnostics. The technology aims to simplify diagnostic procedures by leveraging non-invasive imaging. This partnership expands DiagnosTear’s capabilities in developing painless, accessible diagnostic solutions.